|
English
|
正體中文
|
简体中文
|
Total items :0
|
|
Visitors :
52906670
Online Users :
878
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
|
|
|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"yen shen lu"
Showing items 6-15 of 149 (15 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata T.; Nakamura K.; Yonemori K.; Noguchi E.; Watanabe M.; Sohn J.; YEN-SHEN LU; Yap Y.-S.; Tamura K.; Fujiwara Y. |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
|
Lien H.-C.; Lee Y.-H.; Chen I.-C.; Lin C.-H.; Chen T.W.-W.; Lu Y.-T.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer
|
Fasching P.A.; Delea T.E.; YEN-SHEN LU; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong A.; Kim H.-J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:14:58Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; YEN-SHEN LU; Chuang E.Y.; Thiery J.P.; Huang C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-12-21T23:17:41Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2− advanced breast cancer
|
Fasching, Peter A.; Delea, Thomas E.; YEN-SHEN LU; De Boer, Richard; Hurvitz, Sara A.; Moynahan, Aaron; Chandiwana, David; Lanoue, Brad; Hu, Huilin; Thuerigen, Astrid; O’shaughnessy, Joyce |
| 臺大學術典藏 |
2021-11-21T23:19:52Z |
Genomic profiling of premenopausal HR+ and HER2– metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Vázquez, Rafael Villanueva; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu; YEN-SHEN LU |
Showing items 6-15 of 149 (15 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
